Sonendo, Inc. on Path to Breakeven in the Second Half of 2026

Audio By Carbonatix

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Mar 16, 2026--

Sonendo, Inc. (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today reported select preliminary financial results for the year ended December 31, 2025 and other business updates.

Select Financial Updates 1

• Generated $28.6 million of total revenue for the full year of 2025, including $23.4 million, or approximately 82%, from recurring sales of procedure-related consumables and services;
• Reported an increase in gross margin to 41.9% for the full year of 2025, up 460 basis points compared to 2024;
• Significantly reduced loss from operations to $13.5 million in 2025 from loss of $29.4 million in 2024, and adjusted EBITDA 2 loss to $10.4 million in 2025 from loss of $23.0 million in 2024, driven by improved operational efficiencies;
• Significantly reduced free cash flow burn 2 to $10.9 million in 2025 from $24.8 million in 2024; and
• The Company expects to achieve positive free cash flow 2 and positive adjusted EBITDA 2 in the second half of 2026.

On November 17, 2025, Sonendo entered into a strategic collaboration with a European-based dental company and secured exclusive rights to sell high-quality products in North America. This collaboration enables Sonendo to offer a comprehensive suite of endodontic consumable products, complementing its existing portfolio solutions and enhancing its ability to meet the full range of customer needs. The Company expects this strategic collaboration to bring significant cost savings to GentleWave customers, drive more demand for the GentleWave Procedure, and support Sonendo’s revenue and gross margin growth.

As the first step of this strategic collaboration, Sonendo launched FlowLogic™ endodontic files in the first quarter of 2026. Sonendo expects FlowLogic files to compete with the best performing endodontic files in the industry, while offered to GentleWave customers at a significant discount.

“I'm pleased to report continued strong execution on our path to profitability. Through disciplined operational improvements, we significantly reduced operating expenses while driving greater efficiencies across the organization. This contributed to a meaningful improvement in our adjusted EBITDA performance. At the same time, we successfully maintained our revenue base, demonstrating the resilience of our core business and the value our GentleWave Procedure continues to deliver to endodontists and their patients. More than 1.9 million patients have been treated with the GentleWave System so far,” said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. “We further strengthened our portfolio by adding high-quality ancillary products. This strategic addition enables us to provide a more complete suite of endodontic consumables, which we believe will substantially lower the cost per root canal procedure for our customers—enhancing their practice economics while expanding our addressable market and supporting long-term revenue growth.”

About Sonendo

Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices.

For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.

1 The 2025 financial information presented in this release has not been audited.
2 See additional information included in the Company’s Form 8-K filed with the Securities and Exchange Commission on November 12, 2024 for additional information about the Company’s use of these non-GAAP financial measures.

Forward-Looking Statements

This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the Company’s expectations regarding its future financial performance, including its ability to breakeven in the second half of 2026; its expectations regarding its strategic collaboration with the European-based dental company; and the ability of FlowLogic files to compete with other endodontic files. In addition, the select preliminary financial results for the year ended December 31, 2025 in this news release are preliminary, are not a comprehensive statement of financial results for the period and are provided prior to completion of all internal and external review and audit procedures and therefore are subject to adjustment. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company’s actual results to differ materially from these forward-looking statements include, but are not limited to: the Company’s need to raise capital and its ability to continue as a going concern; the level of adoption and demand for the Company’s product offerings; the Company’s ability to execute and fulfill the potential of its strategic collaboration with the European-based dental company; changes to the Company’s financial results for the full-year ended December 31, 2025 due to the completion of financial closing procedures and final adjustments; and other risks and uncertainties as are described in detail in the “Risk Factors” section of the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025 and available at www.sec.gov. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260316143036/en/

CONTACT: Investor Contact:

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH HEALTH TECHNOLOGY DENTAL GENERAL HEALTH BIOTECHNOLOGY

SOURCE: Sonendo

Copyright Business Wire 2026.

PUB: 03/16/2026 09:50 PM/DISC: 03/16/2026 09:50 PM

http://www.businesswire.com/news/home/20260316143036/en